Drug Profile

Research programme: proto-oncogene protein c-bcl-2 inhibitors - Seagen/Sanford-Burnham Medical Research Institute

Alternative Names: BI-97C1; ONT-701; Sabutoclax

Latest Information Update: 18 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanford-Burnham Medical Research Institute
Developer Cascadian Therapeutics; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University
Class Small molecules
Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

14 Dec 2023 Seagen has been acquired by Pfizer
08 Oct 2020 Seattle Genetics is now called Seagen
09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com